✨ Free AI Report
MacroGenics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research MacroGenics, Inc.
Company Research

MacroGenics, Inc.: Business Overview, Financials & Competitive Analysis

MacroGenics, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). While analysts suggest moderate buy potential with a $3.4 target price, execution risks and regulatory setbacks present high clinical and financial uncertainty. The company faces significant financial distress with an Altman Z-Score of -5.61 indicating potential bankruptcy risk within two years. Recent FDA setbacks include a partial clinical hold on.

What is MacroGenics, Inc.'s industry? MacroGenics, Inc. (macrogenics.com) operates in Biopharmaceutical - Oncology/Immunotherapy. AskCyborg classifies MacroGenics, Inc. under Biopharmaceutical - Oncology/Immunotherapy in its company registry.

MacroGenics is a biotechnology company focused on discovering and developing antibody-based therapeutics for cancer treatment, with its approved product MARGENZA for metastatic HER2-positive breast cancer. The company...

3/ 10Challenged

Cyborg Score thesis

While analysts suggest moderate buy potential with a $3.4 target price, execution risks and regulatory setbacks present high...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology/Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest MacroGenics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for MacroGenics, Inc.

AskCyborg analysts argue the bull and bear cases for MacroGenics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
MacroGenics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

MacroGenics, Inc. Overview

Pro stress-test →

MacroGenics is a biotechnology company focused on discovering and developing antibody-based therapeutics for cancer treatment, with its approved product MARGENZA for metastatic HER2-positive breast cancer. The company maintains collaborations with TerSera Therapeutics, Incyte Corporation, and Gilead Sciences.

Strategic Profile

Pro stress-test →

The company operates a pipeline of bispecific and antibody-drug conjugate candidates targeting tumor-associated antigens and immune checkpoint molecules, including lorigerlimab, MGC026, and MGC028. MacroGenics leverages proprietary Fc engineering and Dual Activating ReTargeting technology to improve antibody functions and eliminate cancer cells.

Competitive Landscape

Pro stress-test →

Top competitors include Moderna, Jazz Pharmaceuticals, and BeiGene. MacroGenics operates in a crowded oncology immunotherapy space where multiple companies develop checkpoint inhibitors and antibody-drug conjugates. The company's focus on proprietary Fc engineering and DART technology differentiates it, though recent safety setbacks have weakened its competitive position.

Industry Context

MacroGenics, Inc. operates in Biopharmaceutical - Oncology/Immunotherapy.

Key facts

Founded: 2000 · Headquarters: Rockville, US · Employees: 391 · Revenue: $149.96M (2024) · Market cap: $126M

What the analysts stress-tested

The top findings that survived the multi-agent debate for MacroGenics, Inc..

  • FDA placed partial clinical hold on lorigerlimab Phase 2 trial in February 2026 due to serious safety events including thrombocytopenia, myocarditis, and fatal septic shock in 41 participants
  • Company had $146.4M in cash and marketable securities as of Sept 2025, with expected partnering payments extending runway into late 2027
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026FDA partial clinical hold on Phase 2 LINNET lorigerlimab trial due to safety concerns
  • November 2025Q3 2025 results showed $72.8M revenue; stopped mCRPC development but progressing LINNET study
  • +1 moreTrack every material event for MacroGenics, Inc. as it happens. Explore monitoring →
Get alerted when MacroGenics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

mRNA Vaccines & ImmunotherapiesLeading mRNA therapeutic platform for cancer and infectious diseases→Oncology & Psychiatry TherapeuticsDiversified biopharmaceutical company with oncology focus→Oncology & ImmunotherapyChinese-based global biopharmaceutical company developing cancer therapies→

Compare MacroGenics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

MacroGenics, Inc. operates in Biopharmaceutical - Oncology/Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology/Immunotherapy research →
NEW · MCP server

Ask your AI assistant about MacroGenics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare MacroGenics, Inc. and its top competitor on Cyborg Score”
“What did MacroGenics, Inc. do this quarter?”
“Is MacroGenics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does MacroGenics, Inc. do?+
MacroGenics is a biotechnology company focused on discovering and developing antibody-based therapeutics for cancer treatment, with its approved product MARGENZA for metastatic HER2-positive breast cancer. The company...
What is MacroGenics, Inc.'s Cyborg Score?+
MacroGenics, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are MacroGenics, Inc.'s main competitors?+
Named competitors include mRNA Vaccines & Immunotherapies, Oncology & Psychiatry Therapeutics, Oncology & Immunotherapy. The full competitive landscape is in the AskCyborg report.
How can I get the full MacroGenics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the MacroGenics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track MacroGenics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Syndax Pharmaceuticals, Inc.7Puma Biotechnology, Inc.7Zai Lab Limited6Genenta Science4BioAtla, Inc.4Mersana Therapeutics, Inc.4Propanc Biopharma, Inc.